Exponent (NASDAQ:EXPO) Stock Price Expected to Rise, UBS Group Analyst Says

Exponent (NASDAQ:EXPO) had its price objective boosted by equities researchers at UBS Group from $72.00 to $82.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the business services provider’s stock. UBS Group‘s price target would indicate a potential upside of 2.17% from the company’s current price.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. upped their price objective on Exponent from $90.00 to $100.00 and gave the stock an “overweight” rating in a report on Friday. Weiss Ratings upgraded Exponent from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, October 9th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Exponent currently has an average rating of “Moderate Buy” and a consensus price target of $91.00.

Exponent Stock Performance

Shares of NASDAQ:EXPO opened at $80.26 on Friday. Exponent has a 52-week low of $51.91 and a 52-week high of $83.18. The firm has a fifty day moving average of $70.19 and a 200 day moving average of $66.64. The firm has a market capitalization of $3.82 billion, a PE ratio of 34.59 and a beta of 0.66.

Exponent (NASDAQ:EXPO) last released its earnings results on Thursday, October 29th. The business services provider reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. Exponent had a return on equity of 34.61% and a net margin of 17.40%. The business had revenue of $173.73 million for the quarter, compared to analysts’ expectations of $149.64 million. During the same quarter in the prior year, the firm earned $0.55 earnings per share. The firm’s revenue was up 11.7% on a year-over-year basis. On average, sell-side analysts forecast that Exponent will post 2.33 EPS for the current fiscal year.

Insider Transactions at Exponent

In related news, CEO Catherine Corrigan sold 1,707 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $66.28, for a total transaction of $113,139.96. Following the sale, the chief executive officer owned 129,108 shares of the company’s stock, valued at $8,557,278.24. The trade was a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Exponent

Institutional investors and hedge funds have recently made changes to their positions in the business. Chicago Partners Investment Group LLC bought a new stake in shares of Exponent in the 3rd quarter worth approximately $226,000. Covestor Ltd grew its stake in shares of Exponent by 10.3% in the 3rd quarter. Covestor Ltd now owns 2,050 shares of the business services provider’s stock worth $134,000 after buying an additional 192 shares during the last quarter. Bridge City Capital LLC grew its stake in shares of Exponent by 21.6% in the 3rd quarter. Bridge City Capital LLC now owns 49,231 shares of the business services provider’s stock worth $3,221,000 after buying an additional 8,729 shares during the last quarter. Vise Technologies Inc. purchased a new position in Exponent during the third quarter valued at $343,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Exponent during the third quarter valued at $216,000. Institutional investors own 92.37% of the company’s stock.

Exponent Company Profile

Exponent, Inc is a science and engineering consulting company that helps clients investigate complex technical issues, manage risks, and develop solutions. Its consultants work across disciplines including engineering, materials science, biomechanics, human factors, environmental science, health, data sciences, and economics.

The company provides failure analysis, product safety and testing, accident reconstruction, environmental and health assessments, regulatory support, and expert testimony.